Envy Medical, a maker of non-invasive skin rejuvenation therapies, has received a growth capital investment from HCP & Company. The new funding from HCP will support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare products.
Envy Medical develops, markets and sells non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The company’s lead products include SilkPeel and Dermalinfusion. Envy is also the exclusive global licensor of skin brightening peptides including Lumixyl, which was developed at Stanford University. The company is based in Westlake Village, CA (www.envymedical.com).
“Looking across the professional skincare and physician dispensed markets, we recognize how very well positioned Envy is to be a dominant player in its market,” said Carlos Signoret, HCP Partner and Co-founder.
HCP & Company makes growth equity and buyout investments of $5 million to $25 million in lower-middle market companies that have revenues of at least $10 million and positive EBITDA. Sectors of interest include business services, consumer products, education, and healthcare services. HCP was founded in 2003 and has $215 million in capital under management. The firm is headquartered in Chicago (www.hcpcompany.com).
“This is the first time in Envy’s history that we have taken on outside growth capital, and we did so with unanimous board and shareholder support,” said Curtis Cluff, Chief Executive Officer. “That support is due in large part to HCP’s business acumen and an understanding that they bring significant experience to the table as Envy accelerates growth towards becoming a major global player in the specialized skincare market.”
Intrepid Investment Bankers (www.intrepidib.com) advised Envy Medical on this transaction.
2014 PEPD • Private Equity’s Leading News Magazine • 6-4-14